BioNTech raises $325M series B round to advance cancer pipeline
BioNTech has raised $325M in a private fundraising round. The series B positions the immuno-oncology company to advance its clinical pipeline and grow its manufacturing footprint.
Germany-based BioNTech now has seven candidates in eight clinical trials. The company’s most advanced assets are derived from its mRNA platform, which established it as a rival to CureVac and Moderna, but its pipeline now also features cell therapies, small molecules, and immune checkpoint modulators.
